PEPTIDES·INDEX
79 peptides463 listingsUpdated 2h agoBuild My Stack
Library

Testosterone Propionate

Testosterone esterified with propionate, a short-acting oil-based injectable. Reference entry for the calculators, not tracked for price.

Reference compound, not sold here. Profile for research context only.

StatusPrescription
Class17β-propionate (C3) ester of testosterone; short-acting oil-depot androgen; Schedule III controlled substance in the US
RouteIntramuscular

Overview

Testosterone propionate is the propionate ester of testosterone: the parent hormone with a three-carbon chain on its 17β-hydroxyl — the shortest of the common esters and the first injectable one to reach the clinic. This is a reference entry, not a product the index tracks; no propionate listings or prices appear here. It exists so the parent page can say honestly what the short end of the ester spectrum looks like. Its regulatory position is unusual: no FDA-approved human propionate product is currently listed — DailyMed returns only Synovex H, a Zoetis cattle implant — while in the UK and other markets it is an authorised prescription medicine as the 30 mg component of Sustanon 250 (Aspen). The approved status shown reflects that authorisation and the historical US approval, not a current US label. Schedule III class-wide; prohibited under WADA class S1. Nothing here is dosing or treatment advice.

Chemistry#

C22H32O3, 344.5 g/mol, CAS 57-85-2 (PubChem; OECD TG 441 prints 57-82-5), PubChem CID 5995. The chain is propionate — straight, C3 — so about 84% of the mass is testosterone (288.4/344.5, arithmetic from the two sourced weights), the highest testosterone fraction of the four esters profiled. The steroid core is unchanged; the short chain is why the depot empties quickly.

Formulation#

No US human product. The only regulatory formulation with a current label is Sustanon 250: per 1 mL ampoule in refined arachis oil, 30 mg testosterone propionate with 60 mg phenylpropionate, 60 mg isocaproate and 100 mg decanoate — 176 mg of testosterone in total. The SmPC says one 1 mL injection per three weeks is usually adequate and that plasma testosterone returns to the lower limit of normal in approximately 21 days; it gives no half-life. The FDA's historical listing is Perandren 2% ointment, an NDA withdrawn in 1971 per the 1996 Federal Register. No subcutaneous product exists.

History#

Testosterone was synthesised in 1935 by Butenandt and by Ruzicka, and Nieschlag records testosterone propionate, with its short half-life, as the early injectable ester that followed. By 1937 Korenchevsky and colleagues were publishing prolonged propionate treatment studies in castrated rats in the Biochemical Journal. Secondary sources attribute a 1937 commercial launch to Schering AG as Testoviron; that attribution was not verified against a primary document and is flagged as such. A 1963 California Medicine review names propionate among the androgens then used for disseminated breast cancer in women. From the mid-1950s the longer-acting enanthate displaced it as the main preparation.

How it works

The ester is inert until hydrolysed; what acts is testosterone, so mechanism — androgen-receptor agonism directly and via dihydrotestosterone, feedback suppression of pituitary LH and of spermatogenesis — is the parent's and is described on the testosterone profile.

Pharmacokinetics#

We publish no half-life for this ester, and say so plainly: there is no regulatory label stating one, and the only primary human pharmacokinetic paper does not report one. Fujioka et al. (1986) gave normal men a single 25 mg IM dose of deuterium-labelled propionate and followed ester and labelled testosterone by GC-MS; the abstract reports that plasma ester held at roughly 2–4 ng/mL from 3 to 36 hours and that labelled testosterone stayed above the physiological level for about 48 hours, with the ester gradually transferred from the injection site to the circulation — a time course, not a fitted half-life. Secondary figures disagree: the Nieschlag/Behre Andrology preparations table gives 0.8 days (mean residence time 1.5 days), encyclopaedia prose says 2 days, and compounding-pharmacy pages claim 4–4.5 days without a primary source. Whatever the number, it is an apparent, absorption-limited half-life of a short oil depot, and the short depot is why Sustanon pairs 30 mg of propionate with three longer esters.

Evidence

Human data for the ester alone are thin and mostly historical, hence a human-data score of 3. Every study below used testosterone propionate specifically. Reference androgen: OECD Test Guideline 441, the Hershberger bioassay adopted 7 September 2009, names testosterone propionate as the reference androgen agonist its validation studies were conducted with. Preclinical BPH model: propionate-induced benign prostatic hyperplasia in rats is a widely used model (a 2024 Frontiers in Pharmacology study is one example). Human pharmacokinetics: Fujioka 1986, 25 mg IM with stable-isotope labelling. Early comparisons: a 1954 human anabolic comparison with cyclopentylpropionate and a 1954 mouse total-body-irradiation survival study. Blend component: Sustanon 250, where it supplies early onset. Historical oncology: the 1963 review of hormonal treatment of disseminated breast cancer. No modern randomised trial of propionate alone is cited here.

Anecdotal reports community-reported

What people describe in forums, blogs and uncontrolled clinic write-ups — experiential and unverified, not clinical evidence and not medical advice.

  • Post-injection pain (PIP)commonly reported

    Propionate is widely described as the ester that 'burns': users report swelling and pain that made standing difficult after 0.5 mL sub-Q in a thigh, and some say the pain never faded over years of intramuscular use. Common verdicts are that it belongs intramuscular in delts or glutes in small volumes, that carrier oil and brand matter, and a minority report no pain at all with any brand.

  • Irritation vs infectionoccasionally reported

    Users describe a hot, bulbous lump above a quad site three days after a first propionate shot in an unfamiliar carrier oil; replies split between a reaction to the oil, a shallow injection and a staph infection, and it ended in a precautionary antibiotic course. Several say propionate only ever gives them redness and swelling, never a boil, and prefer delts or glutes over quads.

  • Mood, libido and the morning 'kick'commonly reported

    Users who moved from longer esters to daily propionate often describe better morning drive, libido and erectile function, no estradiol or hematocrit issues, and like that dose changes show within days. Others feel no difference from enanthate at matched frequency or say the 'kick' is just a higher peak, and some report anxiety or head pressure when the dose overlaps a cypionate base or exceeds about 20 mg/day.

  • Injection frequency and stabilitycommonly reported

    Daily injection is treated as the minimum, with some dosing at night to peak in the morning; every-other-day or three-times-weekly use is criticised for large swings, one reported lab pattern falling to a quarter of its post-shot high by the next morning. Fans say the deliberate variation suits them; critics call propionate '1930s medicine' with more oil per milligram and no advantage over cypionate pinned often.

  • Scepticism about 10 mg/day 'microdosing'commonly reported

    Claims that 10 mg/day gives 'superman energy' while natural production continues between shots are flatly rejected: users say any exogenous dose shuts down production and that 70 mg/week replaces less than it suppresses. Those happy on propionate report 15–30 mg/day and advise against breaks; a minority find 30 mg disrupts mood and prefer less.

Safety

Class risks — erythrocytosis, androgenic skin effects, gynecomastia, fluid retention, suppressed spermatogenesis, mood change, venous thromboembolism, and the abuse syndrome — are the parent's and are set out on the testosterone profile. Because no current US human label exists, there is no FDA boxed warning or REMS specific to this ester; class testosterone warnings apply. The Sustanon 250 SmPC cautions that testosterone may raise blood pressure and that the product should be used with caution in men with hypertension, and its vehicle is arachis oil, relevant to peanut allergy. The practical hazard specific to propionate is not in any label: with no approved single-ester product in the US, what circulates under this name is compounded or unlicensed, and nothing on this page describes such products. Prescription-only Schedule III; the safety score of 3 mirrors the parent's and would be lower for unlabeled or underground products.

Reported side effects

Reported in published literature and user reports. Not a complete list, and not medical advice.

  • Class effects of testosterone — erythrocytosis, acne, gynecomastia, fluid retention, suppressed spermatogenesis, mood changes, venous thromboembolism (see the testosterone profile)
  • Blood-pressure rise and fluid retention — Sustanon 250 SmPC cautions use in men with hypertension
  • Hypersensitivity to the vehicle — Sustanon 250 is in arachis (peanut) oil
  • Injection-site reactions; a short ester implies frequent injections

If severe or unexpected symptoms occur, contact a qualified medical professional. Peptides·Index does not provide medical advice.

Cautions discuss with a clinician

Use caution or avoid if
  • Known or suspected carcinoma of the prostate or breast in men (class contraindication; Sustanon 250 SmPC)
  • Women who are pregnant — virilisation of the female fetus (class)
  • Serious cardiac, hepatic or renal disease — fluid retention and edema risk (class)
  • Peanut allergy — Sustanon 250 is formulated in arachis oil (SmPC section 2)
Interactions
  • Oral anticoagulants (warfarin)Androgens increase sensitivity; the anticoagulant dose may need reduction (class, testosterone labels)
  • Insulin and other antidiabetic drugsAndrogens may lower blood glucose and reduce insulin requirements (class, testosterone labels)
  • Thyroid function testsAndrogens lower thyroxine-binding globulin, reducing total T4 while free hormone stays normal (class, testosterone labels)

Timeline commonly reported

  1. Hours 3–36

    After a single 25 mg IM dose of deuterium-labelled propionate in normal men, plasma ester held at roughly 2–4 ng/mL from 3 to 36 hours (Fujioka 1986).

  2. Hours 0–48

    Labelled testosterone stayed above the physiological level for about 48 hours in the same study — the short depot that defines this ester.

  3. Days to 3 weeks (blend)

    Within Sustanon 250 the 30 mg propionate fraction provides early onset while three longer esters carry the 3-week interval; the SmPC says plasma testosterone returns to the lower limit of normal in approximately 21 days.

FAQ

Is testosterone propionate a peptide?

No. It is testosterone esterified with propionic acid — a three-carbon chain on the 17β-hydroxyl — giving C22H32O3, 344.5 g/mol. It is a reference entry so the parent testosterone page can compare esters; the index does not track propionate products or prices.

What is the half-life of testosterone propionate?

We do not publish a number. No regulatory label states one, and the only primary human pharmacokinetic paper (Fujioka 1986) reports a time course — labelled testosterone above physiological levels for about 48 hours after 25 mg IM — without a fitted half-life. Secondary sources disagree: a textbook table gives 0.8 days, encyclopaedia prose 2 days, and compounding-pharmacy pages 4–4.5 days with no primary source. What is certain is that it is the shortest of the common esters.

Is testosterone propionate FDA-approved?

Not currently for human use. DailyMed lists only Synovex H, a Zoetis cattle implant combining propionate with estradiol benzoate; the FDA's historical listing is Perandren 2% ointment, an NDA withdrawn in 1971. In the UK and other markets it is an authorised medicine as the 30 mg component of Sustanon 250. The fda_status on this page reflects that authorised, prescription-only status rather than a current US label.

Why is propionate blended with other esters?

Sustanon 250 pairs 30 mg propionate with 60 mg phenylpropionate, 60 mg isocaproate and 100 mg decanoate per mL in arachis oil — 176 mg of testosterone in total. The short ester gives early onset while the longer ones carry the labelled 3-week interval.

Sources

Starting references for the library summary. These are not dosing instructions or medical advice.

For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.